Markus Jerling

1.8k total citations
44 papers, 1.3k citations indexed

About

Markus Jerling is a scholar working on Molecular Biology, Pharmacology and Pharmacology. According to data from OpenAlex, Markus Jerling has authored 44 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Pharmacology and 10 papers in Pharmacology. Recurrent topics in Markus Jerling's work include Pharmacogenetics and Drug Metabolism (10 papers), Cardiac electrophysiology and arrhythmias (6 papers) and Epilepsy research and treatment (6 papers). Markus Jerling is often cited by papers focused on Pharmacogenetics and Drug Metabolism (10 papers), Cardiac electrophysiology and arrhythmias (6 papers) and Epilepsy research and treatment (6 papers). Markus Jerling collaborates with scholars based in Sweden, United States and Uganda. Markus Jerling's co-authors include Leif Bertilsson, Ulf Bondesson, Leif Lindström, Hisham Abdallah, France Mentré, Yann Merlé, Alain Mallet, Urban Hellgren, Leif Bertilsson and Folke Sjöqvist and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Blood.

In The Last Decade

Markus Jerling

44 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Jerling Sweden 20 308 302 283 267 235 44 1.3k
Feng Guo China 23 240 0.8× 105 0.3× 725 2.6× 129 0.5× 319 1.4× 87 1.7k
Nada Božina Croatia 23 482 1.6× 386 1.3× 242 0.9× 75 0.3× 423 1.8× 86 1.5k
Ronald Schmidt Germany 25 135 0.4× 91 0.3× 614 2.2× 119 0.4× 162 0.7× 40 2.2k
Edward L. Posvar United States 16 87 0.3× 275 0.9× 547 1.9× 132 0.5× 414 1.8× 30 1.7k
Christine Alvey United States 22 167 0.5× 252 0.8× 268 0.9× 35 0.1× 259 1.1× 46 1.4k
Jan Jaap van Lier United States 18 130 0.4× 77 0.3× 318 1.1× 162 0.6× 123 0.5× 38 1.0k
Mila Lovrić Croatia 16 269 0.9× 165 0.5× 162 0.6× 77 0.3× 211 0.9× 48 842
Adriaan Cleton United States 19 88 0.3× 394 1.3× 213 0.8× 36 0.1× 121 0.5× 58 978
Peter Zannikos United States 19 107 0.3× 95 0.3× 215 0.8× 77 0.3× 204 0.9× 57 1.0k
Inge‐Britt Lindén Finland 15 74 0.2× 113 0.4× 261 0.9× 374 1.4× 46 0.2× 35 1.2k

Countries citing papers authored by Markus Jerling

Since Specialization
Citations

This map shows the geographic impact of Markus Jerling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Jerling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Jerling more than expected).

Fields of papers citing papers by Markus Jerling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Jerling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Jerling. The network helps show where Markus Jerling may publish in the future.

Co-authorship network of co-authors of Markus Jerling

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Jerling. A scholar is included among the top collaborators of Markus Jerling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Jerling. Markus Jerling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Damme, Philip Van, Petra Tilkin, Ann D’Hondt, et al.. (2020). Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study. Brain Communications. 2(2). fcaa160–fcaa160. 14 indexed citations
2.
Lindström, Erik, Ian Henderson, Ylva Terelius, et al.. (2018). Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711. Journal of Translational Medicine. 16(1). 125–125. 37 indexed citations
3.
Paul, Gesine, Olof Zachrisson, Andrea Varrone, et al.. (2015). Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients. Journal of Clinical Investigation. 125(3). 1339–1346. 83 indexed citations
4.
5.
Ekman, Simon, Johan Harmenberg, Jan‐Erik Frödin, et al.. (2015). A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial. Acta Oncologica. 55(2). 140–148. 17 indexed citations
6.
Lindström, Erik, Urszula Grabowska, Markus Jerling, & Charlotte Edenius. (2014). MIV-711, a highly selective cathepsin K inhibitor, reduces biomarkers of bone resorption and cartilage degradation in healthy subjects. Osteoarthritis and Cartilage. 22. S197–S197. 4 indexed citations
7.
Mwebaza, Norah, Markus Jerling, Lars L. Gustafsson, et al.. (2013). Comparable Lumefantrine Oral Bioavailability when Co‐administered With Oil‐Fortified Maize Porridge or Milk in Healthy Volunteers. Basic & Clinical Pharmacology & Toxicology. 113(1). 66–72. 4 indexed citations
8.
Obua, Celestino, Urban Hellgren, Lars L. Gustafsson, et al.. (2008). Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. British Journal of Clinical Pharmacology. 65(4). 493–501. 30 indexed citations
9.
Jerling, Markus. (2006). Clinical Pharmacokinetics of Ranolazine. Clinical Pharmacokinetics. 45(5). 469–491. 114 indexed citations
10.
11.
Jerling, Markus, et al.. (2005). Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clinical Pharmacology & Therapeutics. 78(3). 288–297. 44 indexed citations
12.
Hendel, Robert C., John J. Mahmarian, Timothy M. Bateman, et al.. (2004). 1170-141 Initial results regarding the safety, tolerability, and hemodynamic effects of CVT-3146, a selective adenosine A2A agonist, in patients undergoing pharmacologic stress SPECT myocardial perfusion imaging. Journal of the American College of Cardiology. 43(5). A367–A367. 2 indexed citations
13.
Jönsson, Erik G., et al.. (1998). Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia. Psychiatric Genetics. 8(1). 25–28. 14 indexed citations
14.
Jerling, Markus, Yann Merlé, France Mentré, & Alain Mallet. (1997). Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. British Journal of Clinical Pharmacology. 44(5). 447–453. 51 indexed citations
15.
Hellgren, Urban, et al.. (1997). Enantioselective pharmacokinetics of mefloquine during long‐term intake of the prophylactic dose. British Journal of Clinical Pharmacology. 44(2). 119–124. 13 indexed citations
16.
Jerling, Markus, et al.. (1996). The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol*. Clinical Pharmacology & Therapeutics. 59(4). 423–428. 67 indexed citations
17.
Hellgren, Urban, et al.. (1996). Comparison between concentrations of racemic mefloquine, its separate enantiomers and the carboxylic acid metabolite in whole blood serum and plasma. European Journal of Clinical Pharmacology. 51(2). 171–173. 4 indexed citations
18.
Jerling, Markus. (1996). Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response. European Journal of Drug Metabolism and Pharmacokinetics. 21(2). 113–121. 3 indexed citations
19.
Jerling, Markus, Leif Lindström, Ulf Bondesson, & Leif Bertilsson. (1994). Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine. Therapeutic Drug Monitoring. 16(4). 368–374. 224 indexed citations
20.
Jerling, Markus, Leif Bertilsson, & Folke Sjöqvist. (1994). The Use of Therapeutic Drug Monitoring Data to Document Kinetic Drug Interactions. Therapeutic Drug Monitoring. 16(1). 1–12. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng Guo Breakdown of academic impact, for papers by Nada Božina Breakdown of academic impact, for papers by Ronald Schmidt Breakdown of academic impact, for papers by Edward L. Posvar Breakdown of academic impact, for papers by Christine Alvey Breakdown of academic impact, for papers by Jan Jaap van Lier Breakdown of academic impact, for papers by Mila Lovrić Breakdown of academic impact, for papers by Adriaan Cleton Breakdown of academic impact, for papers by Peter Zannikos Breakdown of academic impact, for papers by Inge‐Britt Lindén
Rankless by CCL
2026